



## **Alistair Henry**

**Executive Vice President  
Chief Scientific Officer**

**Joined UCB in 2004 via the acquisition of  
Celltech (joining Celltech in March 1998)**

**Appointed in 2024**

**Date of birth: 1967**

**Nationality: British**

### **Introduction & Professional experience**

Alistair Henry leads UCB's research and early development organisation with the main goal of bringing innovation to patients and their families, helping them to live the lives they choose.

Alistair joined Celltech from King's College London in 1998, and consequently UCB at the acquisition in 2004. Throughout that time Alistair has led various teams and projects but always with a view to delivering innovative medicines for patients. He has been intimately associated with the biologics platform and with the technologies that underpin both small and large molecule drug discovery. He has played a key role in the progression of medicines such as Evenity, Bimzelx, and Rystigo. He has collaborated widely and published extensively.

Since 2023 Alistair has led the UK Research operation for UCB. Prior to that he was responsible for the global Discovery and head of all molecule platforms.

### **Education**

Alistair graduated from King's College London where he received a BSc in Immunology and his PhD in Biophysics.

